+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine



Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine



Cancer Science 106(11): 1493-1498



The present study attempted to identify T helper epitope long peptides capable of inducing cytotoxic T lymphocytes (CTL) from Lck antigen (p56(Lck) ), the src family tyrosine kinase, which is known to be aberrantly expressed in metastatic cancers cells, in order to develop a long peptide-based cancer vaccine for HLA-A2(+) cancer patients. Based on the biding motif to the HLA-DR and HLA-A2 alleles, 94 peptides were prepared from the Lck antigen. These peptides were screened for their reactivity to immunoglobulin G (IgG) from plasma of cancer patients, followed by testing of their ability to induce both CD4(+) and CD8(+) T lymphocytes showing not only peptide-specific IFN-γ production but cytotoxicity against HLA-A2(+) cancer cells from peripheral blood mononuclear cells (PBMC) of HLA-A2(+) cancer patients. Among 94 peptides tested, the three T helper epitope long peptides and their inner CTL epitope short peptides with HLA-A2 binding motifs were frequently recognized by IgG of cancer patients, and efficiently induced both CD4(+) IFN-γ(+) and CD8(+) IFN-γ(+) T lymphocytes. Patients' PBMC stimulated with these long peptides showed cytotoxicity against HLA-A2(+) Lck(+) cancer cells in HLA-class I and HLA-class II dependent manners. These three peptides might be useful for long peptide-based vaccines for HLA-A2(+) cancer patients with Lck(+) tumor cells.

(PDF emailed within 0-6 h: $19.90)

Accession: 058040268

Download citation: RISBibTeXText

PMID: 26331453

DOI: 10.1111/cas.12805


Related references

Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. Immunology Letters 161(1): 20-30, 2015

Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. British Journal of Cancer 97(12): 1648-1654, 2007

Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. Human Vaccines and Immunotherapeutics 9(5): 1073-1077, 2014

First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Science 103(1): 150-153, 2012

Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients. Cancer Science 100(11): 2167-2174, 2009

Identification of HLA-A2 binding peptides derived from the MUC1 protein for broadly applicable vaccine therapies. Blood 92(10 SUPPL 1 PART 1-2): 499A, Nov 15, 1998

Identification of glypican-3-derived long peptides activating both CD8 + and CD4 + T cells; prolonged overall survival in cancer patients with Th cell response. Oncoimmunology 5(1): E1062209, 2016

New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients. Prostate 62(3): 233-242, 2004

Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clinical Cancer Research 12(19): 5841-5849, 2006

Identification of HLA-A*0201/-A*2402-restricted CTL epitope-peptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response. Oncology Reports 25(2): 469-476, 2011

Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease. Frontiers in Bioscience 11: 46-58, 2005

Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease. Frontiers in Bioscience 11: 46-58, 2006

Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients. International Journal of Oncology 29(3): 577-587, 2006

Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunology, ImmunoTherapy 56(5): 689-698, 2006

Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer. Human Vaccines and Immunotherapeutics 10(11): 3201-3213, 2015